Koala trial doses first patient with novel KMA‑targeting CAR‑T Australian teams advance first‑in‑human multiple myeloma therapy Read More
Heparegenix wins orphan drug status for darizmetinib Designation supports development for post‑hepatectomy liver failure Read More
IMAVVY approved as first targeted therapy for wAIHA New treatment reduces pathogenic IgG while preserving B‑cell function Read More
Nxera partner gains acceptance for NBI‑1117567 Phase 2 study to assess muscarinic M1 agonist in Alzheimer’s cognition Read More
Jemperli accepted for priority review by US FDA sBLA covers dMMR/MSI‑H stage II–III rectal cancer Read More